It looks like Eli Lilly is setting up a major investment in Houston. Eli Lilly and Co. confirmed Sept. 23 that the Bayou City will be part of its domestic manufacturing push.
David Ricks, Lilly’s CEO and chairman, joined Texas Gov. Greg Abbott to officially announce that the pharmaceutical giant will build a $6.5 billion manufacturing plant in the Generation Park development.
In recent years, Eli Lilly has focused heavily on expanding its portfolio of treatments for weight management and other chronic conditions. Notably, drugs like Mounjaro and Zepbound have gained attention for their effectiveness in treating obesity and related health issues. To meet increasing demand, the company announced a $6.5 billion investment in a new state-of-the-art biomanufacturing facility in Houston, Texas. This facility is expected to create more than 600 jobs and will support production of advanced therapies, including orforglipron, an oral medication aimed at metabolic diseases.
READ: Eli Lilly to buy SiteOne for $1 billion (
Eli Lilly and Company, founded in 1876 and based in Indianapolis, Indiana, is a major global pharmaceutical leader known for its innovations in areas like diabetes, oncology, immunology, and neuroscience. The company has a rich history, including pioneering the mass production of insulin and developing key medications such as Prozac and Cymbalta. As of 2025, Eli Lilly is among the most valuable pharmaceutical firms worldwide, with operations spanning over 18 countries and products sold in around 125 nations.
The $6.5 billion figure is a significant bump from the $5.9 billion Lilly had indicated it would invest when the Indianapolis-based drugmaker filed an application for a tax abatement through Texas’ Jobs, Energy, Technology and Innovation program earlier this year.
Eli Lilly remains committed to pushing the boundaries of pharmaceutical research and development, investing in innovative technologies and expanding manufacturing capabilities. Their strategic focus on both groundbreaking therapies and sustainable growth positions the company to maintain its leadership role in the competitive global healthcare industry. This combination of legacy and innovation continues to drive Eli Lilly’s mission to improve health outcomes worldwide.